Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 14 points (-0.1%) at 16,929 as of Tuesday, June 10, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 966 issues advancing vs. 1,989 declining with 165 unchanged. The Health Care sector currently is unchanged today versus the S&P 500, which is down 0.2%. On the negative front, top decliners within the sector include CR Bard ( BCR), down 3.9%, Jazz Pharmaceuticals ( JAZZ), down 3.6%, Actavis ( ACT), down 1.7%, Biogen Idec ( BIIB), down 1.6% and Regeneron Pharmaceuticals ( REGN), down 1.6%. Top gainers within the sector include Illumina ( ILMN), up 1.4%, Bristol-Myers Squibb Company ( BMY), up 0.7%, Teva Pharmaceutical Industries ( TEVA), up 0.6% and Gilead ( GILD), up 0.6%. TheStreet would like to highlight 3 stocks pushing the sector lower today: 3. Eli Lilly and ( LLY) is one of the companies pushing the Health Care sector lower today. As of noon trading, Eli Lilly and is down $0.58 (-1.0%) to $59.16 on light volume. Thus far, 1.3 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 4.8 million shares. The stock has ranged in price between $59.09-$59.82 after having opened the day at $59.82 as compared to the previous trading day's close of $59.74. Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and has a market cap of $66.8 billion and is part of the drugs industry. Shares are up 17.1% year-to-date as of the close of trading on Monday. Currently there are 5 analysts that rate Eli Lilly and a buy, 2 analysts rate it a sell, and 7 rate it a hold. TheStreet Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.